Table 3.

Results of All Outcomes for the Main Analyses

Survival Measure	Main Analysis (13 trials)
	HR	95% CI	P	Absolute 5-Year Survival Benefit (%)
Overall disease-free survival	0.78	0.70 to 0.87	.000005	8
Locoregional disease-free survival	0.76	0.68 to 0.86	.000003	9
Metastases-free survival	0.81	0.72 to 0.91	.0004	7
Locoregional disease-free interval	0.74	0.64 to 0.86	.00009	6
Metastases-free interval	0.83	0.71 to 0.99	.037	4

NOTE. Two trials in which additional adjuvant chemotherapy was administered on the treatment arm are excluded.